Basic Information
DUROMINE CAPSULE 30 mg
CAPSULE
Regulatory Information
SIN01256P
May 16, 1988
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
XA08AA01
Company Information
INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED
INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED
Active Ingredients
Strength: 30 mg
Detailed Information
Contraindications
**CONTRAINDICATIONS** Pulmonary artery hypertension; existing heart valve abnormalities or heart murmurs; moderate to severe arterial hypertension; cerebro-vascular disease; severe cardiac disease including arrhythmias, advanced arteriosclerosis; known hypersensitivity to sympathomimetic drugs; hyperthyroidism; agitated states or a history of psychiatric illnesses including anorexia nervosa and depression; glaucoma; history of drug/ alcohol abuse or dependence; concomitant treatment with Monoamine Oxidase (MAO) Inhibitors or within 14 days following their administration.
Indication Information
**INDICATIONS** Duromine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (BMI) of 30 kg/m2 or greater. The treatment with Duromine can be initiated in overweight patients with a lower BMI (25 to 29.9 kg/m2) which increases the risk of morbidity from a number of disorders. Secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.